SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
Shujing LiSien ZhaoNianhai LiangShaoting ZhangLiangying ZhangLiangji ZhouAnbu LiuXu CaoJinhai TianYuanyuan YuZhaoyang FanKun XiaoMing WangHui ZhaoRu BaiJianmin SunPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2023)
Our results suggested that SPRY4 acts as negative feedback of primary KIT mutants in GISTs by inhibiting KIT expression and activation. It can increase the sensitivity of primary KIT mutants to imatinib. In contrast, secondary KIT mutants are resistant to the inhibition of SPRY4.